Common name:
Meglumine
meglumin(Turkish)
เมกลูมีน(Thai)
メグルミン(Japanese)
葡甲胺(Chinese)
메글루민(Korean)
Uses of Meglumine compound
It is used as a diagnostic drug for gastrointestinal radiography (if barium sulfate is contraindicated) and for the diagnosis of vascular diseases, biliary tract disorders, brain disorders, bovine or splenic vein disorders, renal and urinary tract disorders, and disc and joint disorders. Be. It is also used as a contrast agent in the diagnosis of joint and disc diseases, contrast enhancers in computed tomography of the body, gastrointestinal disorders and heart diseases.
Mechanism of action of meglumine compound
Organic compounds of iodine detect the structure of the target tissue when passing through different channels of the body with X-rays. The intensity of radiation absorption depends on the iodine concentration.
Pharmacokinetics of meglumine compound
It is absorbed in small amounts through the gastrointestinal tract. After intravertebral injection, it is rapidly absorbed into the joint, intramuscularly, into the bladder or into the spleen, and after intravenous injection into the arteries, it is rapidly distributed in intercellular fluids. Its binding to plasma proteins is low and if the kidney is functioning normally, its plasma half-life is 30-60 minutes. Excretion of the drug is via the kidneys. In case of kidney failure, the half-life of the drug will be 20-40 hours.
Contraindications to the use of meglumine compound
It should not be used in cases of history of hypersensitivity to iodine, iodinated or penicillin contrast agents, history of allergy or asthma, severe cardiovascular disease, dehydration, pheochromocytoma, renal failure, recent neurological attacks. This medicine should not be used in the special cases mentioned below:
In case of pulmonary hypertension (for angiocardiography), in case of homocystinuria (for cerebral angiography), in case of Burger disease, severe ischemia with infection (for peripheral arteriography), in case of coagulation defects (for cholangiography and splenoportheography and x-ray), in Subarachnoid (for computed tomography of the brain), in the absence of urinary incontinence, diabetes mellitus (for excretory urography), obstruction or acute upper urinary tract infection (for recurrent urography), and in the presence of or within infection (for arthrography and Discography), and in case of infection of the upper respiratory tract (for discography).
Side effects of meglumine compound
Side effects usually depend on the drug concentration, viscosity, amount and speed of administration. Due to the low amount of iodine in the product or released from it may cause hyperthyroidism. Convulsions and death may occur if the drug is injected at a concentration of 60% inside the subarachnoid space. Acute renal failure has been reported after intravascular injection of diatrizoate during urinary tract radiography, especially in patients with renal impairment due to other diseases. False allergic reactions, severe and abnormal weakness due to hypotension, wheezing or abnormal breathing, nausea and vomiting, nausea and vomiting, diarrhea, metallic taste, dizziness, headache, nasal inflammation, cough, itching, Visual impairment, sneezing, enlarged salivary glands, decreased or increased heart rate, ECG disorders, cardiac arrhythmias, suspicion, and cardiac arrest are relatively common. Localized complications include tissue pain and injury at the injection site, thrombophlebitis, thrombosis, venous spasm, and embolism.
Drug Interactions Meglumin Compound
Concomitant use of vasoconstrictors can increase the risk of neurological effects. Concomitant use with beta antagonists causes anaphylactoid reactions. Taking this drug with oral gallbladder radiotherapy increases the risk of kidney toxicity. Concomitant use of this drug with antihypertensive drugs can cause a severe drop in blood pressure. Administration of interleukin 2 with this drug increases the risk of delayed side effects of intravenous contrast agents.
Warnings Meglumine Compound
- Injectable meglumine diatrizoate may cause seizures in infants, especially with repeated injections.
- Due to the osmotic effect of these drugs on urinary excretion and dehydration, it may worsen in infants, young children or elderly patients, especially if they have urinary incontinence, urinary incontinence, diabetes or previous dehydration. In order to prevent dehydration, the patient should be given enough fluids before the test. Elderly patients are more likely to develop kidney failure.
- Use with caution in the presence of atherosclerosis, increased intracranial pressure, primary or metastatic brain lesions.
- Due to cross-allergy, patients sensitive to iodinated radioactive contrast agents may also be allergic to this drug.
Meglumin Compound Drug Recommendations
- The use of these contrast agents is not recommended for myelography or examination of cysts or dorsal sinuses that may be associated with the subarachnoid space.
- To prevent aspiration of gastric contents, do not consume food before the test, but dilute fluids are not forbidden.
- Consumption of iodinated contrast agents may interfere with thyroid function tests, blood cell counts, blood coagulation tests, and some specific urine tests.
- Prior to administration of the original dose, intravenous injection of 0.5-1 ml of the product is recommended for sensitivity testing. However, tools must be available to prevent allergic reactions.
- In very young or old people and patients with disabilities, patients with hypertension, liver failure, advanced heart disease, pheochromocytoma, sickle cell anemia, hyperthyroidism and patients prone to renal failure increase the risk of side effects. Give.
- Electrocardiography is necessary for early detection of arrhythmias during coronary arteriography and angiocardiography.
- Glucocorticoids and antihistamines are recommended to reduce the incidence and severity of severe reactions in high-risk patients (such as asthma, history of allergy or penicillin allergy, dehydration, history of epileptic seizures, and pheochromocytoma).
- Temporary cessation of breastfeeding (at least 24 hours) after medication is recommended.
Was this helpful?
0 / 0
